YB-1 Is a Novel Target for the Inhibition of α-Adrenergic-Induced Hypertrophy

Jacqueline Heger1, Stefan Partsch1, Claudia Harjung1

  • 1Institute of Physiology, Justus Liebig University, 35392 Giessen, Germany.

Insights

The transcription factor Y-box binding protein 1 (YB-1) protects heart cells from hypertrophy. Reduced YB-1 levels in heart failure patients suggest YB-1 is crucial for preventing heart damage.

Area of Science:

  • Cardiovascular Biology
  • Molecular Cardiology
  • Cellular Signaling

Background:

  • Cardiac hypertrophy, driven by sympathetic nervous system activation, is a precursor to heart failure.
  • The transcription factor Y-box binding protein 1 (YB-1) may modulate hypertrophy by interacting with relevant transcription factors.
  • YB-1 expression is decreased in human heart failure patients with ischemic cardiomyopathy.

Purpose of the Study:

  • To investigate the role of Y-box binding protein 1 (YB-1) in cardiomyocyte hypertrophy.
  • To determine if YB-1 influences the development of heart failure.

Main Methods:

  • Small interfering RNA (siRNA) was used to downregulate YB-1 in H9C2 cells and rat adult cardiomyocytes (CMs).
  • Adenovirus-mediated overexpression of YB-1 (AdYB-1) was performed in CMs, with AdGFP as a control.
  • Hypertrophic responses were assessed under phenylephrine (PE) and growth differentiation factor 15 (GDF15) stimulation.

Main Results:

  • YB-1 downregulation using siRNA exacerbated hypertrophic growth, mediated by PI3K under PE stimulation.
  • YB-1 overexpression in CMs inhibited PE-induced hypertrophic growth but not GDF15-induced growth.
  • YB-1 overexpression increased the mRNA expression of Regulator of G-protein signaling 2 (RGS2) under PE stimulation.

Conclusions:

  • Y-box binding protein 1 (YB-1) acts as a protective factor against phenylephrine-induced hypertrophic growth in cardiomyocytes.
  • Downregulation of YB-1, observed in human heart failure, may impair the heart's defense against hypertrophic stimuli, promoting disease progression.
  • YB-1 represents a significant signaling molecule with potential as a therapeutic target for heart failure.

Related Concept Videos

Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
448
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
813
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.7K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
880
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.5K
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
2.6K